Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CBUS 
Cibus Global LLC (CBUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CBUS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.4
1 Year Target Price $14.4
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -81.23% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 73.76M USD | Price to earnings Ratio - | 1Y Target Price 14.4 |
Price to earnings Ratio - | 1Y Target Price 14.4 | ||
Volume (30-day avg) 4 | Beta 1.76 | 52 Weeks Range 1.22 - 6.77 | Updated Date 08/28/2025 |
52 Weeks Range 1.22 - 6.77 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.3 | Actual -0.61 |
Profitability
Profit Margin - | Operating Margin (TTM) -1923.47% |
Management Effectiveness
Return on Assets (TTM) -10.5% | Return on Equity (TTM) -158.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68311495 | Price to Sales(TTM) 15.22 |
Enterprise Value 68311495 | Price to Sales(TTM) 15.22 | ||
Enterprise Value to Revenue 14.1 | Enterprise Value to EBITDA -1.15 | Shares Outstanding 52540500 | Shares Floating 36417941 |
Shares Outstanding 52540500 | Shares Floating 36417941 | ||
Percent Insiders 33.53 | Percent Institutions 29 |
Upturn AI SWOT
Cibus Global LLC
Company Overview
History and Background
Cibus Global LLC is a biotechnology company founded in 2001. It specializes in gene-editing technologies for agriculture to improve crop traits without introducing foreign DNA. Initially focused on canola, Cibus has expanded its technology to other crops and markets.
Core Business Areas
- Trait Development: Develops novel crop traits using gene-editing technologies to enhance yield, disease resistance, and other desirable characteristics.
- Seed Production: Produces and markets seeds with improved traits developed through its gene-editing platform.
- Technology Licensing: Licenses its gene-editing technology to other agricultural companies and research institutions.
Leadership and Structure
Cibus Global LLC is led by a team of experienced executives in agriculture, biotechnology, and business. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Canola Seeds: Cibus's primary product is canola seeds enhanced with traits developed through its gene-editing platform. Market share is variable and growing, with competition from Bayer CropScience, Corteva Agriscience, and BASF. Revenue generation is still evolving.
- Gene-Editing Technology: Cibus licenses its Rapid Trait Development System (RTDS) to other companies. Details of the revenue generated or the number of users is not publicly available. Competitors in the CRISPR and gene editing space include CRISPR Therapeutics, Editas Medicine and Intellia Therapeutics
Market Dynamics
Industry Overview
The agricultural biotechnology industry is rapidly evolving, driven by the need for sustainable and efficient food production. Gene-editing technologies are gaining acceptance as a precise and effective tool for crop improvement.
Positioning
Cibus is positioned as a leader in gene-editing for agriculture, with a focus on developing non-GMO solutions. Its competitive advantage lies in its proprietary RTDS technology.
Total Addressable Market (TAM)
The total addressable market for gene-edited crops is estimated to be in the tens of billions of dollars. Cibus is positioned to capture a significant share of this market through its trait development and licensing activities.
Upturn SWOT Analysis
Strengths
- Proprietary RTDS gene-editing technology
- Non-GMO approach
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited commercial product portfolio
- High R&D expenses
- Reliance on regulatory approvals
- Competition from larger agricultural companies
Opportunities
- Expansion into new crops and markets
- Strategic partnerships and collaborations
- Increasing adoption of gene-editing technologies
- Growing demand for sustainable agriculture
Threats
- Regulatory hurdles and uncertainty
- Public perception of gene-edited crops
- Competition from alternative technologies
- Economic downturns affecting agricultural markets
Competitors and Market Share
Key Competitors
Competitive Landscape
As a private company financial information is unavailable to determine competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not publicly available for the company.
Future Projections: Future projections are not publicly available as Cibus is not a publicly traded company.
Recent Initiatives: Recent initiatives focus on expanding the application of its gene-editing technology to new crops and developing strategic partnerships.
Summary
Cibus Global LLC is a biotechnology company focused on gene-editing for agriculture with a strong proprietary technology. Its main weakness is the limited availability of public financial data due to its private status. Opportunities lie in expanding its reach into new crops and markets, but the regulatory environment poses a risk. The company's non-GMO approach gives it a unique selling point in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cibus Global LLC Website
- Industry Reports
- General News Sources
Disclaimers:
The information provided is based on publicly available sources and general industry knowledge. Due to Cibus Global LLC being a private company, certain financial and operational data is limited. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cibus Global LLC
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2023-06-01 | Co-Founder, Interim CEO, President, COO & Director Dr. Peter R. Beetham B.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 157 | Website https://www.cibus.com |
Full time employees 157 | Website https://www.cibus.com | ||
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.